WHO Informal Consultation on standardization and evaluation of BCG vaccines Geneva, Switzerland 22-23 September 2009

Vaccine

Volumn 28, Issue 43, 2010, Pages 6945-6950

  Ho, Mei M ^a   Southern, James ^b   Kang, Hye Na ^c   Knezevic, Ivana ^c  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b Ministry of Health   (South Africa)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

BCG; Standardization; WHO

Indexed keywords

ANTIBIOTIC AGENT; BCG VACCINE;

BACTERIAL STRAIN; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MANUFACTURE; DRUG QUALITY; DRUG SCREENING; HUMAN; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; STANDARDIZATION; SWITZERLAND; TUBERCULOSIS; VIRUS ATTENUATION; WORLD HEALTH ORGANIZATION;

BCG VACCINE; CLINICAL TRIALS AS TOPIC; MYCOBACTERIUM BOVIS; QUALITY CONTROL; REFERENCE STANDARDS; VACCINES, ATTENUATED; WORLD HEALTH ORGANIZATION;

EID: 77957374873     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.07.086     Document Type: Conference Paper

References (47)

1. Corbel M.J., Fruth U., Griffiths E., Knezevic I. Report on a WHO consultation on the characterisation of BCG strains, Imperial College, London 15-16 December 2003. Vaccine 2004, 22(21-22):2675-2680.
2. Ho M.M., Corbel M.J., Knezevic I., Roumiantzeff M. Report on a WHO consultation on the characterisation of BCG vaccines, WHO, Geneva, Switzerland 8-9 December 2004. Vaccine 2005, 23(50):5700-5704.
3. Knezevic I., Corbel M.J. WHO discussion on the improvement of the quality control of BCG vaccines. Pasteur Institute, Paris, France, 7 June 2005. Vaccine 2006, 24(18):3874-3877.
4. WHO Expert Committee on Biological Standardization. Requirements for freeze-dried BCG vaccine. World Health Organization Technical Report Series 1987;745:60-92.
5. Sun R., Skeiky Y.A., Izzo A., Dheenadhayalan V., Imam Z., Penn E., et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 2009, 27(33):4412-4423.
6. Sambandamurthy V.K., Derrick S.C., Jalapathy K.V., Chen B., Russell R.G., Morris S.L., et al. Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis. Infect Immun 2005, 73(2):1196-1203.
7. Sambandamurthy V.K., Derrick S.C., Hsu T., Chen B., Larsen M.H., Jalapathy K.V., et al. Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine 2006, 24(37-39):6309-6320.
8. Martin C., Williams A., Hernandez-Pando R., Cardona P.J., Gormley E., Bordat Y., et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 2006, 24(17):3408-3419.
9. Asensio J.A., Arbues A., Perez E., Gicquel B., Martin C. Live tuberculosis vaccines based on phoP mutants: a step towards clinical trials. Expert Opin Biol Ther 2008, 8(2):201-211.
10. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Nasser E.A., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 2005, 115(9):2472-2479.
11. Hoft D.F., Blazevic A., Abate G., Hanekom W.A., Kaplan G., Soler J.H., et al. A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis 2008, 198(10):1491-1501.
12. European Pharmacopoeia. Strasbourg, Cedex, France: Directorate for the Quality of Medicines of the Council of Europe (EDQM), BCG vaccine, freeze-dried. 01/2008:2008;0163. p. 759-61.
13. Tchilian E.Z., Desel C., Forbes E.K., Bandermann S., Sander C.R., Hill A.V., et al. Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ure C hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis. Infect Immun 2009, 77(2):622-631.
14. Verreck F.A., Vervenne R.A., Kondova I., van Kralingen K.W., Remarque E.J., Braskamp G., et al. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One 2009, 4(4):e5264.
15. Skeiky Y.A., Dietrich J., Lasco T.M., Stagliano K., Dheenadhayalan V., Goetz M.A., et al. Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen. Vaccine 2009.
16. Hawkridge T., Scriba T.J., Gelderbloem S., Smit E., Tameris M., Moyo S., et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis 2008, 198(4):544-552.
17. Whelan K.T., Pathan A.A., Sander C.R., Fletcher H.A., Poulton I., Alder N.C., et al. Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A. PLoS One 2009, 4(6):e5934.
18. Parra M., Yang A.L., Lim J., Kolibab K., Derrick S., Cadieux N., et al. Development of a murine mycobacterial growth inhibition assay for evaluating vaccines against Mycobacterium tuberculosis. Clin Vaccine Immunol 2009, 16(7):1025-1032.
19. Brosch R., Gordon S.V., Garnier T., Eiglmeier K., Frigui W., Valenti P., et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci USA 2007, 104(13):5596-5601.
20. Seki M., Honda I., Fujita I., Yano I., Yamamoto S., Koyama A. Whole genome sequence analysis of Mycobacterium bovis bacillus Calmette-Guerin (BCG) Tokyo 172: a comparative study of BCG vaccine substrains. Vaccine 2009, 27(11):1710-1716.
21. Brosch R., Gordon S.V., Buchrieser C., Pym A.S., Garnier T., Cole S.T. Comparative genomics uncovers large tandem chromosomal duplications in Mycobacterium bovis BCG Pasteur. Yeast 2000, 17(2):111-123.
22. Honda I., Seki M., Ikeda N., Yamamoto S., Yano I., Koyama A., et al. Identification of two subpopulations of Bacillus Calmette-Guerin (BCG) Tokyo172 substrain with different RD16 regions. Vaccine 2006, 24(23):4969-4974.
23. Shibayama K., Mochida K., Yagi T., Mori S., Arakawa Y., Yamamoto S. Quantification of two variant strains contained in freeze-dried Japanese BCG vaccine preparation by real-time PCR. Biologicals 2007, 35(2):139-143.
24. Bedwell J., Kairo S.K., Behr M.A., Bygraves J.A. Identification of substrains of BCG vaccine using multiplex PCR. Vaccine 2001, 19(15-16):2146-2151.
25. Markey K, Ho MM, Choudhury B, Seki M, Ju L, Castello-Branco LR, et al. Report of an international collaborative study to evaluate the suitability of multiplex PCR as an identity assay for different sub-strains of BCG vaccine, submitted for publication. (GENERIC) Ref Type: Generic.
26. Mostowy S., Tsolaki A.G., Small P.M., Behr M.A. The in vitro evolution of BCG vaccines. Vaccine 2003, 21(27-30):4270-4274.
27. Leung A.S., Tran V., Wu Z., Yu X., Alexander D.C., Gao G.F., et al. Novel genome polymorphisms in BCG vaccine strains and impact on efficacy. BMC Genomics 2008, 9:413.
28. Benevolo-de-Andrade T.C., Monteiro-Maia R., Cosgrove C., Castello-Branco L.R. BCG Moreau Rio de Janeiro: an oral vaccine against tuberculosis-review. Mem Inst Oswaldo Cruz 2005, 100(5):459-465.
29. Monteiro-Maia R., Ortigao-de-Sampaio M.B., Pinho R.T., Castello-Branco L.R. Modulation of humoral immune response to oral BCG vaccination by Mycobacterium bovis BCG Moreau Rio de Janeiro (RDJ) in healthy adults. J Immune Based Ther Vaccines 2006, 4:4.
30. Cox J.S., Chen B., McNeil M., Jacobs W.R. Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature 1999, 402(6757):79-83.
31. Reed M.B., Domenech P., Manca C., Su H., Barczak A.K., Kreiswirth B.N., et al. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 2004, 431(7004):84-87.
32. Hotter G.S., Wards B.J., Mouat P., Besra G.S., Gomes J., Singh M., et al. Transposon mutagenesis of Mb0100 at the ppe1-nrp locus in Mycobacterium bovis disrupts phthiocerol dimycocerosate (PDIM) and glycosylphenol-PDIM biosynthesis, producing an avirulent strain with vaccine properties at least equal to those of M. bovis BCG. J Bacteriol 2005, 187(7):2267-2277.
33. Rodriguez-Alvarez M., Mendoza-Hernandez G., Encarnacion S., Calva J.J., Lopez-Vidal Y. Phenotypic differences between BCG vaccines at the proteome level. Tuberculosis (Edinb) 2009, 89(2):126-135.
34. Horwitz M.A., Harth G., Dillon B.J., Maslesa-Galic S. Commonly administered BCG strains including an evolutionarily early strain and evolutionarily late strains of disparate genealogy induce comparable protective immunity against tuberculosis. Vaccine 2009, 27(3):441-445.
35. Hayashi D., Takii T., Fujiwara N., Fujita Y., Yano I., Yamamoto S., et al. Comparable studies of immunostimulating activities in vitro among Mycobacterium bovis bacillus Calmette-Guerin (BCG) substrains. FEMS Immunol Med Microbiol 2009, 56(2):116-128.
36. Castillo-Rodal A.I., Castanon-Arreola M., Hernandez-Pando R., Calva J.J., Sada-Diaz E., Lopez-Vidal Y. Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB/c model of progressive pulmonary tuberculosis. Infect Immun 2006, 74(3):1718-1724.
37. Jensen S.E., Hubrechts P., Klein B.M., Haslov K.R. Development and validation of an ATP method for rapid estimation of viable units in lyophilised BCG Danish 1331 vaccine. Biologicals 2008, 36(5):308-314.
38. Ho M.M., Markey K., Rigsby P., Jensen S.E., Gairola S., Seki M., et al. Report of an international collaborative study to establish the suitability of using modified ATP assay for viable count of BCG vaccine. Vaccine 2008, 26(36):4754-4757.
39. Ho MM, Markey K, Rigsby P, Hockley J, Corbel MJ. Report of an International collaborative study to establish the First WHO Reference Reagents for BCG vaccine of three different sub-strains, submitted for publication. (GENERIC) Ref Type: Generic.
40. Trunz B.B., Fine P., Dye C. Effect of BCG vaccination on childhood tuberculosis meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006, 367(9517):1173-1180.
41. Hawkridge A., Hatherill M., Little F., Goetz M.A., Barker L., Mahomed H., et al. Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial. BMJ 2008, 337:a2052.
42. Rodrigues L.C., Pereira S.M., Cunha S.S., Genser B., Ichihara M.Y., de Brito S.C., et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 2005, 366(9493):1290-1295.
43. Pulickal A.S., Fernandez G.V. Comparison of the prevalence of tuberculosis infection in BCG vaccinated versus nonvaccinated school age children. Indian Pediatr 2007, 44(5):344-347.
44. Eisenhut M., Paranjothy S., Abubakar I., Bracebridge S., Lilley M., Mulla R., et al. BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay. Vaccine 2009, 27(44):6116-6120.
45. Kagina B.M., Abel B., Bowmaker M., Scriba T.J., Gelderbloem S., Smit E., et al. Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response. Vaccine 2009, 27(40):5488-5495.
46. Mansoor N., Scriba T.J., de Kock M., Tameris M., Abel B., Keyser A., et al. HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guerin vaccine. J Infect Dis 2009, 199(7):982-990.
47. Hesseling A.C., Marais B.J., Gie R.P., Schaaf H.S., Fine P.E., Godfrey-Faussett P., et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 2007, 25(1):14-18.